While drugs remain the cornerstone of medicine, herbal medicine is an important comedication worldwide. Thus, precision medicine ought to face this clinical reality and develop “companion diagnostics” for drugs as well as herbal medicines. Yet, many are in denial with respect to the extent of use of traditional/herbal medicines, overlooking that a considerable number of contemporary therapeutic drugs trace their discovery from herbal medicines. This expert review underscores that absent such appropriate attention on both classical drug therapy and herbal medicines, precision medicine biomarkers will likely not stand the full test of clinical practice while patients continue to use both drugs and herbal medicines and, yet the biomarker research and applications focus only (or mostly) on drug therapy. This asymmetry in biomarker innovation strategy needs urgent attention from a wide range of innovation actors worldwide, including governments, research funders, scientists, community leaders, civil society organizations, herbal, pharmaceutical, and insurance industries, policymakers, and social/political scientists. We discuss the various dimensions of a future convergence map between herbal and conventional medicine, and conclude with a set of concrete strategies on how best to integrate biomarker research in a realm of both herbal and drug treatment. Africa, by virtue of its vast experience and exposure in herbal medicine and a “pregnant” life sciences innovation ecosystem, could play a game-changing role for the “birth” of biomarker-informed personalized herbal medicine in the near future. At this critical juncture when precision medicine initiatives are being rolled out worldwide, precision/personalized herbal medicine is both timely and essential for modern therapeutics, not to mention biomarker innovations that stand the test of real-life practices and implementation in the clinic and society.
Get full access to this article
View all access options for this article.
References
1.
AbidiA. (2013). Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother, 4, 230–237.
2.
AdamsBM, BanksHT, KwonHD, and TranHT. (2004). Dynamic multidrug therapies for HIV: Optimal and STI control approaches. Math Biosci Eng, 1, 223–241.
3.
Al DisiSS, AnwarMA, and EidAH. (2015). Anti-hypertensive herbs and their mechanisms of action: Part I. Front Pharmacol, 6, 323.
4.
American Diabetes AssociationAD. (2010). Standards of medical care in diabetes—2010. Diabetes Care, 33Suppl 1, S11–S61.
5.
AndreF, MardisE, SalmM, et al. (2014). Prioritizing targets for precision cancer medicine. Ann Oncol, 25, 2295–2303.
6.
AndrejaM. (2010). Metformin–more than “gold standard” in the treatment of type 2 diabetes mellitus. Diabetol Croat, 39, 95–104.
7.
AntinoriA, Di BiagioA, MarcotullioS, et al. (2017). Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol, 40, 86–98.
8.
AnwarMA, Al DisiSS, and EidAH. (2016). Anti-hypertensive herbs and their mechanisms of action: Part II. Front Pharmacol, 7, 50.
9.
ApaydinEA, MaherAR, ShanmanR, et al. (2016). A systematic review of St. John's wort for major depressive disorder. Syst Rev, 5, 148.
10.
Arauz-PachecoC, ParrottMA, RaskinP, and AssociationAD. (2003). Treatment of hypertension in adults with diabetes. Diabetes Care 26 Suppl, 1, S80–S82.
11.
ArtsEJ, and HazudaDJ. (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med, 2, a007161.
12.
AwortweC, BouicPJ, MasimirembwaCM, and RosenkranzB. (2013). Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa–implications for herb-drug interactions. Drug Metab Lett, 7, 83–95.
13.
BackemarL, DjärvT, WikmanA, et al. (2013). The role of diabetes and other co-morbidities on survival after esophageal cancer surgery in a population-based study. Am J Surg, 206, 539–543.
14.
BackemarL, LagergrenP, DjärvT, et al. (2015). Comorbidities and risk of complications after surgery for esophageal cancer: A nationwide cohort study in Sweden. World J Surg, 39, 2282–2288.
15.
BarlowDJ, BurianiA, EhrmanT, et al. (2012). In-silico studies in Chinese herbal medicines' research: Evaluation of in-silico methodologies and phytochemical data sources, and a review of research to date. J Ethnopharmacol, 140, 526–534.
16.
BidonC, LachuerJL, MolgóJ, et al. (2009). The extract of Ginkgo biloba EGb 761 reactivates a juvenile profile in the skeletal muscle of sarcopenic rats by transcriptional reprogramming. PLoS One, 4, e7998.
17.
BoffitoM, PozniakA, KearneyBP, et al. (2005). Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob Agents Chemother, 49, 4386–4389.
18.
BozkurtB, AguilarD, DeswalA, et al. (2016). Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: A scientific statement from the American Heart Association Circulation. Circulation, 134, e535–e578.
19.
BrittonKA, GazianoJM, and DjousséL. (2009). Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail, 11, 1129–1134.
20.
BrittonL-MP, SovaP, BelisleS, et al. (2014). A proteomic glimpse into the initial global epigenetic changes during HIV infection. Proteomics, 14, 2226–2230.
21.
BrookRD, AppelLJ, RubenfireM, et al. (2013). Beyond medications and diet: Alternative approaches to lowering blood pressure: A scientific statement from the American Heart Association. Hypertension, 61, 1360–1383.
22.
BrownDW, GilesWH, and GreenlundKJ. (2007). Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens, 20, 338–341.
23.
BuettnerC, YehGY, PhillipsRS, MittlemanMA, and KaptchukTJ. (2006). Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother, 40, 83–95.
24.
BurgerD, Van Der HeidenI, La PorteC, et al. (2006). Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol, 61, 148–154.
25.
CajkaT, and FiehnO. (2014). Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. Trends Anal Chem, 61, 192–206.
26.
CanellosGP, RosenbergSA, FriedbergJW, ListerTA, and DevitaVT. (2014). Treatment of Hodgkin lymphoma: A 50-year perspective. J Clin Oncol, 32, 163–168.
27.
CefaluWT, StephensJM, and RibnickyDM. (2011). Diabetes and herbal (Botanical) medicine. In: Herbal Medicine: Biomolecular and Clinical Aspects. BenzieIFF, Wachtel-GalorS, eds. Boca Raton, FL: CRC Press/Taylor & Francis.
28.
ChaE, and FongL. (2011). Immunotherapy for prostate cancer: Biology and therapeutic approaches. J Clin Oncol, 29, 3677–3685.
29.
ChamieK, DaskivichTJ, KwanL, et al. (2012). Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med, 27, 492–499.
30.
ChangA. (2010). Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer, 71, 3–10.
31.
ChangCC, CraneM, ZhouJ, et al. (2013). HIV and co-infections. Immunol Rev, 254, 114–142.
32.
ChenJM, HeranBS, and WrightJM. (2009). Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. In: Cochrane Database of Systematic Reviews. ChenJM, ed. Chichester, UK: John Wiley & Sons, Ltd., p. CD007187.
33.
ChenS, ZhouJ, XiM, et al. (2013). Pharmacogenetic variation and metformin response. Curr Drug Metab, 14, 1070–1082.
34.
ChobanianAV, BakrisGL, BlackHR, et al. (2003). The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA, 289, 2560–2572.
35.
ChoiH-C, KimS-J, SonK-Y, OhB-J, and ChoB-L. (2013). Metabolic effects of Aloe vera gel complex in obese prediabetes and early non-treated diabetic patients: Randomized controlled trial. Nutrition, 29, 1110–1114.
36.
ChrysantSG, and ChrysantGS. (2017). Herbs used for the treatment of hypertension and their mechanism of action. Curr Hypertens Rep, 19, 77.
37.
ChuI-H, BodnarJA, BowmanRN, and WhiteEL. (1997). Determination of vincristine and vinblastine in Catharanthus roseus plants by high performance liquid chromatography/electrospray ionization mass spectrometry. J Liquid Chromatogr Relat Technol, 20, 1159–1174.
38.
ClishCB. (2015). Metabolomics: An emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud, 1, a000588.
39.
CohenCJ, Andrade-VillanuevaJ, ClotetB, et al. (2011). Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet, 378, 229–237.
40.
CollinsFS, and VarmusH. (2015). A new initiative on precision medicine. N Engl J Med, 372, 793–795.
41.
ComisRL. (2005). The current situation: Erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist, 10, 467–470.
42.
ConsoliA, and FormosoG. (2013). Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?. Diabetes Obes Metab, 15, 967–977.
43.
CrinòL, ScagliottiG, MarangoloM, et al. (1997). Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol, 15, 297–303.
44.
CusatoJ, TomaselloC, SimieleM, et al. (2016). Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents, 47, 117–123.
45.
DavidSP, JohnsonSG, BergerAC, et al. (2015). Making personalized health care even more personalized: Insights from activities of the IOM genomics roundtable. Ann Fam Med, 13, 373–380.
46.
DayS, CoombesRC, Mcgrath-LoneL, SchoenbornC, and WardH. (2017). Stratified, precision or personalised medicine? Cancer services in the “real world” of a London hospital. Sociol Health Illn, 39, 143–158.
47.
de La TailleA, ButtyanR, HayekO, et al. (2000). Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol, 164, 1229–1234.
48.
DepsPD, NasserS, GuerraP, et al. (2007). Adverse effects from multi-drug therapy in leprosy: A Brazilian study. Lepr Rev, 78, 216–222.
49.
DiehlV, FranklinJ, HasencleverD, et al. (1998). BEACOPP: A new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 9 Suppl, 5, S67–S71.
50.
DiNicolantonioJJ, FaresH, NiaziAK, et al. (2015). beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: A review of the literature. Open Heart, 2, e000230.
51.
DongL, WangW, LiA, et al. (2015). Clinical next generation sequencing for precision medicine in cancer. Curr Genomics, 16, 253–263.
52.
DoosL, RobertsEO, CorpN, and KadamUT. (2014). Multi-drug therapy in chronic condition multimorbidity: A systematic review. Fam Pract, 31, 654–663.
53.
DrouinP, StandlE, and GroupDMS. (2004). Gliclazide modified release*: Results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab, 6, 414–421.
54.
DrussBG, MarcusSC, OlfsonM, et al. (2001). Comparing the national economic burden of five chronic conditions. Health Aff (Millwood), 20, 233–241.
55.
DuJ, and TangXL. (2014). Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs. J Cancer Res Ther 10 Suppl, 1, 27–37.
56.
DutkowskaAE, and AntczakA. (2016). Comorbidities in lung cancer. Pneumonol Alergol Pol, 84, 186–192.
57.
EckhardU, MarinoG, ButlerGS, and OverallCM. (2016). Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie, 122, 110–118.
58.
EddouksM, MaghraniM, LemhadriA, OuahidiM-L, and JouadH. (2002). Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet). J Ethnopharmacol, 82, 97–103.
59.
EichenauerDA, and EngertA. (2009). Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?. Leuk Lymphoma, 50, 1733–1734.
60.
EkorM. (2014). The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol, 4, 177.
61.
Endale GurmuA, TeniFS, and TadesseWT. (2017). Pattern of traditional medicine utilization among HIV/AIDS patients on antiretroviral therapy at a University Hospital in Northwestern Ethiopia: A Cross-Sectional Study. Evid Based Complement Alternat Med, 2017, 1–6.
62.
FallahzadehMK, DormaneshB, SaghebMM, et al. (2012). Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial. Am J Kidney Dis, 60, 896–903.
63.
FiehnO. (2016). Metabolomics by gas chromatography-mass spectrometry: Combined targeted and untargeted profiling. Curr Protoc Mol Biol, 114, 30.4.1–30.4.32.
64.
FisherE, O'RourkeM, EvansR, KennedyEB, GormanME, and SeagerTP. (2015). Mapping the integrative field: Taking stock of socio-technical collaborations. J Responsible Innovation, 2, 39–61.
65.
FisherE. (2018). Gene drives and the expanding horizon of governance. J Responsible Innovation, 5, S1–S3.
66.
FogariR, DerosaG, ZoppiA, et al. (2007). Effect of telmisartan—Amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens, 20, 417–422.
67.
FooteRL, MolinaJR, KasperbauerJL, et al. (2011). Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: A single-institution experience using aggressive multimodal therapy. Thyroid, 21, 25–30.
68.
ForetzM, and ViolletB. (2015). Therapy: Metformin takes a new route to clinical efficacy. Nature reviews. Endocrinology, 11, 390–392.
69.
FortinM, SoubhiH, HudonC, BaylissEA, and Van Den AkkerM. (2007). Multimorbidity's many challenges. BMJ, 334, 1016–1017.
70.
GaganJ, and Van AllenEM. (2015). Next-generation sequencing to guide cancer therapy. Genome Med, 7, 80.
71.
GailM. (2013). A review of metformin and its place in the diabetes guidelines. S Afr Fam Pract, 55, 504–506.
72.
GaneshJ, and ViswanathanV. (2011). Management of diabetic hypertensives. Indian J Endocrinol Metab 15 Suppl, 4, S374–S379.
73.
GazzardB, DuvivierC, ZaglerC, et al. (2011). Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients. AIDS, 25, 2249–2258.
74.
GeyerCE, ForsterJ, LindquistD, et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355, 2733–2743.
75.
GilsonC, ManickavasagarT, and ChowdhuryS. (2015). Treatment of metastatic prostate cancer. Trends Urol Mens Health, 6, 7–12.
76.
GisvoldO. (1972). Acetyldigoxin and acetyldigitoxin from Digitalis lanata. J Pharm Sci, 61, 1320–1321.
77.
GiuffridaD, and GharibH. (2000). Anaplastic thyroid carcinoma: Current diagnosis and treatment. Ann Oncol, 11, 1083–1089.
78.
GouletJL, FultzSL, RimlandD, et al. (2007). Aging and infectious diseases: Do patterns of comorbidity vary by HIV status, age, and HIV severity?. Clin Infect Dis, 45, 1593–1601.
79.
GreenhalghJ, BagustA, BolandA, et al. (2015). Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): A systematic review and economic evaluation. Health Technol Assess, 19, 1–134.
80.
GroblerAC, MatthewsG, and MolenberghsG. (2014). The impact of missing data on clinical trials: A re-analysis of a placebo controlled trial of Hypericum perforatum (St Johns wort) and sertraline in major depressive disorder. Psychopharmacology (Berl), 231, 1987–1999.
81.
GrossJL, De AzevedoMJ, SilveiroSP, et al. (2005). Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, 28, 164–176.
82.
GuoY, ShiL, HongH, et al. (2013). Studies on abacavir-induced hypersensitivity reaction: A successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci, 56, 119–124.
83.
Gurib-FakimA, and MahomoodallyMF. (2013). African flora as potential sources of medicinal plants: Towards the chemotherapy of major parasitic and other infectious diseases-a review. Jordan J Biol Sci, 6, 77–84.
84.
GustonDH. (2015). Responsible innovation: Who could be against that?. J Responsible Innovation, 2, 1–4.
85.
HeranBS, WongMM, HeranIK, and WrightJM. (2008). Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. In: Cochrane Database of Systematic Reviews. HeranBS, ed. Chichester, UK: John Wiley & Sons, Ltd., p. CD003823.
86.
HouedeN, BeuzebocP, GourgouS, et al. (2015). Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer, 15, 222.
87.
HunterP. (2014). Vaccines against cancer: Despite setbacks, attempts to harness the patient's immune system to fight tumor cells show promise in clinical trials. EMBO Rep, 15, 485–488.
88.
ImaiH, KotegawaT, TsutsumiK, et al. (2008). The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol, 65, 701–707.
89.
IslamKM, JiangX, AnggondowatiT, LinG, and GantiAK. (2015). Comorbidity and survival in lung cancer patients. Cancer Epidemiol Biomarkers Prev, 24, 1079–1085.
90.
JamesPA, OparilS, CarterBL, et al. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311, 507–520.
91.
JohneA, BrockmöllerJ, BauerS, et al. (1999). Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)*1. Clin Pharmacol Ther, 66, 338–345.
92.
KalaitzidisRG, and BakrisGL. (2010). Prehypertension: Is it relevant for nephrologists?. Kidney Int, 77, 194–200.
93.
KearnsB, Lloyd-JonesM, StevensonM, and LittlewoodC. (2013). Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: A NICE single technology appraisal. Pharmacoeconomics, 31, 479–488.
94.
KennardL, and O'ShaughnessyKM. (2016). Treating hypertension in patients with medical comorbidities. BMJ, 352, i101.
95.
KhajehdehiP, PakfetratM, JavidniaK, et al. (2011). Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol, 45, 365–370.
96.
KimmelSE. (2015). Warfarin pharmacogenomics: Current best evidence. J Thromb Haemost 13 Suppl, 1, S266–S271.
97.
KoltermannA, HartkornA, KochE, et al. (2007). Ginkgo biloba extract EGb® 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci, 64, 1715–1722.
98.
KrystJ, KawalecP, and PilcA. (2015). Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 10, e0124279.
99.
KuijpensJL, Janssen-HeijnenML, LemmensVE, et al. (2006). Comorbidity in newly diagnosed thyroid cancer patients: A population-based study on prevalence and the impact on treatment and survival. Clin Endocrinol (Oxf), 64, 450–455.
100.
Kurnat-ThomaEL. (2011). Genetics and genomics: The scientific drivers of personalized medicine. Annu Rev Nurs Res, 29, 27–54.
101.
LalkhenH, ChbM, and MashR. (2015). Multimorbidity in non-communicable diseases in South African primary healthcare. Afr Med J, 105105, 134–138.
102.
LamkanfiM, MuellerJL, VitariAC, et al. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol, 187, 61–70.
103.
Langlois-KlassenD, KippW, JhangriGS, and RubaaleT. (2007). Use of traditional herbal medicine by AIDS patients in Kabarole District, Western Uganda. Am J Trop Med Hyg, 77, 757–763.
104.
LarochelleP, and LacourcièreY. (2014). β-blockers in hypertension: Studies and meta-analyses over the years. Can J Cardiol, 30, S16–S22.
105.
LawesCMM, RodgersA, BennettDA, et al. (2003). Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens, 21, 707–716.
106.
LewingtonS, ClarkeR, QizilbashN, et al. (2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, 1903–1913.
107.
LiY, SteppiA, ZhouY, et al. (2017). Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. Sci Rep, 7, 4747.
108.
LimAK. (2014). Diabetic nephropathy—Complications and treatment. Int J Nephrol Renovasc Dis, 7, 361–381.
109.
LimSS, VosT, FlaxmanAD, et al. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2224–2260.
110.
LinJ-A, and HeP. (2015). Reinventing clinical trials: A review of innovative biomarker trial designs in cancer therapies. Br Med Bull, 114, 17–27.
111.
LinJ-Z, LongJ-Y, WangA-Q, ZhengY, and ZhaoH-T. (2017). Precision medicine: In need of guidance and surveillance. World J Gastroenterol, 23, 5045–5050.
112.
LingC-Q, YueX-Q, and LingC. (2014). Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med, 12, 331–335.
113.
LongAN, and Dagogo-JackS. (2011). Comorbidities of diabetes and hypertension: Mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich), 13, 244–251.
114.
LorencA, AnanthavarathanP, LoriganJ, et al. (2014). The prevalence of comorbidities among people living with HIV in Brent: A diverse London Borough. London J Prim Care, 6, 84–90.
115.
MaddiganSL, FeenyDH, and JohnsonJA. (2005). Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res, 14, 1311–1320.
116.
MarcucciG, PerrottiD, and CaligiuriMA. (2003). Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333–1337, 2003. Clin Cancer Res, 9, 1248–1252.
117.
MariaC, ThallingerR, RadererM, and HejnaM. (2011). Esophageal cancer: A critical evaluation of systemic second-line therapy. J Clin Oncol, 29, 1–6.
118.
MarksLS, DipaolaRS, NelsonP, et al. (2002). PC-SPES: Herbal formulation for prostate cancer. Urology, 60, 369–375; discussion 376–367.
119.
MayM, and SchindlerC. (2016). Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab, 7, 69–83.
120.
MazzoneP, and MekhailT. (2012). Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respir Med, 106, 473–492.
121.
Mccaskill-StevensW, and AbramsJS. (2011). Comorbidities in the aging breast cancer population: Are current assessments leading to improved outcomes?. J Natl Cancer Inst, 103, 1072–1073.
122.
MccormackT, KrauseT, and O'flynnN. (2012). Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract, 62, 163–164.
123.
MccreaJ, CribbA, RushmoreT, et al. (1999). Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther, 65, 348–352.
124.
McGillN. (2015). Public health, prevention to play role in precision medicine: Interventions aimed at individual risks. Nations Health, 45, 1–16.
125.
MillsE, CooperC, SeelyD, and KanferI. (2005). African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J, 4, 19.
126.
MimranA, and WeirMR. (2005). Angiotensin‐receptor blockers and diuretics—Advantages of combination. Blood Press, 14, 6–11.
127.
MitnickCD, WhiteRA, LuC, et al. (2016). Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J, 48, 1160–1170.
128.
ModakM, DixitP, LondheJ, GhaskadbiS, and DevasagayamTPA. (2007). Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr, 40, 163–173.
129.
MogensenCE, NeldamS, TikkanenI, et al. (2000). Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 321, 1440–1444.
130.
MolinaJ-M, CahnP, GrinsztejnB, et al. (2011). Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet, 378, 238–246.
131.
MoserM, and FranklinSS. (2007). Hypertension management: Results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich), 9, 316–323.
132.
MukonzoJK, OwenJS, Ogwal-OkengJ, et al. (2014). Pharmacogenetic-based efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes. PLoS One, 9, e86919.
133.
MusiniVM, NazerM, BassettK, and WrightJM. (2014). Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. In: Cochrane Database of Systematic Reviews. MusiniVM, ed. Chichester, UK: John Wiley & Sons, Ltd., p. CD003824.
134.
NamudduB, KalyangoJN, KaramagiC, et al. (2011). Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda. BMC Public Health, 11, 855.
135.
NelsonM, DockrellD, EdwardsS, et al. (2011a). British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med, 12, 1–5.
136.
NelsonM, StellbrinkH-JR, PodzamczerD, et al. (2011b). A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS, 25, 335–340.
137.
NewmanDJ, and CraggGM. (2007). Natural products as sources of new drugs over the last 25 years. J Nat Prod, 70, 461–477.
138.
NgaimisiE, HabtewoldA, MinziO, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One, 8, e67946.
139.
NguyenCM, MendesMAS, and MaJD. (2011). Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr, 3, RRN1236.
140.
NishioS, WatanabeH, KosugeK, et al. (2005). Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res, 28, 223–227.
141.
NiuJ, WeberJ, and GelbspanD. (2012). Change of HER2 status in metastatic esophageal adenocarcinoma: Heterogeneity of the disease? Case report and review of literature. J Gastrointest Oncol, 3, 358–361.
142.
NlootoM. (2017). Comorbidities of HIV infection and health care seeking behavior among HIV infected patients attending public sector healthcare facilities in KwaZulu-Natal: A cross sectional study. PLoS One, 12, e0170983.
143.
NyanguI, and MokwenaKE. (2015). Experiences and views of hiv-positive patients regarding sesotho traditional medicines for the management of HIV/AIDS in Morija, Lesotho. Afr J Nurs Midwifery, 17, 61–75.
144.
OdusolaAO, StronksK, HendriksME, et al. (2016). Enablers and barriers for implementing high-quality hypertension care in a rural primary care setting in Nigeria: Perspectives of primary care staff and health insurance managers. Glob Health Action, 9, 29041.
145.
OreagbaIA, OshikoyaKA, and AmachreeM. (2011). Herbal medicine use among urban residents in Lagos, Nigeria. BMC Complement Altern Med, 11, 117.
146.
OrisatokiRO, and OguntibejuOO. (2010). The role of Herbal Medicine use in HIV/AIDS treatment. Arch Clin Micro, 1, 1–4.
147.
OyebodeO, KandalaN-B, ChiltonPJ, and LilfordRJ. (2016). Use of traditional medicine in middle-income countries: A WHO-SAGE study. Health Policy Plan, 31, 984–991.
148.
PanL, QiuY, ChenT, et al. (2010). An optimized procedure for metabonomic analysis of rat liver tissue using gas chromatography/time-of-flight mass spectrometry. J Pharm Biomed Anal, 52, 589–596.
149.
PantaloneKM, HobbsTM, WellsBJ, et al. (2015). Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care, 3, e000093.
150.
PelkonenO, PasanenM, LindonJC, et al. (2012). Omics and its potential impact on R&D and regulation of complex herbal products. J. Ethnopharmacol, 140, 587–593.
151.
Piccart-GebhartMJ, ProcterM, Leyland-JonesB, et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659–1672.
152.
PietteJD, and KerrEA. (2006). The impact of comorbid chronic conditions on diabetes care. Diabetes Care, 29, 725–731.
153.
PirmohamedM, BurnsideG, ErikssonN, et al. (2013). A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 369, 2294–2303.
154.
PrueksrisakulT, ChantarangsuS, and ThunyakitpisalP. (2015). Effect of daily drinking of Aloe vera gel extract on plasma total antioxidant capacity and oral pathogenic bacteria in healthy volunteer: A short-term study. J Complement Integr Med, 12, 159–164.
155.
Rafieian-KopaieM, and NasriH. (2012). Silymarin and diabetic nephropathy. J Renal Inj Prev, 1, 3–5.
156.
RayanA, RaiynJ, and FalahM. (2017). Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS One, 12, e0187925.
157.
RibaudoHJ, LiuH, SchwabM, et al. (2010). Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study. J Infect Dis, 202, 717–722.
158.
RigasJR, DragnevKH, and BubisJA. (2005). Docetaxel in the treatment of esophageal cancer. Semin Oncol, 32, S39–S51.
159.
RitchieC. (2007). Health care quality and multimorbidity. Med Care, 45, 477–479.
160.
RizaE, LinosA, PetraliasA, et al. (2015). The effect of Greek herbal tea consumption on thyroid cancer: A case-control study. Eur J Public Health, 25, 1001–1005.
161.
RizzoP, OsipoC, ForemanK, et al. (2008). Rational targeting of Notch signaling in cancer. Oncogene, 27, 5124–5131.
162.
RobertsER, GreenD, and KadamUT. (2014). Chronic condition comorbidity and multidrug therapy in general practice populations: A cross-sectional linkage study. BMJ Open, 4, e005429.
163.
Rodriguez-PenneyAT, IudicelloJE, RiggsPK, et al. (2013). Co-morbidities in persons infected with HIV: Increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS, 27, 5–16.
164.
RojasLBA, GomesMB, GodarziM, et al. (2013). Metformin: An old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr, 5, 6.
165.
RomondEH, PerezEA, BryantJ, et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673–1684.
166.
RosenJE, GardinerP, SaperRB, et al. (2014). Kelp use in patients with thyroid cancer. Endocrine, 46, 123–130.
167.
SahebnasaghA, GhasemiA, AkbariJ, et al. (2017). Successful treatment of acute radiation proctitis with Aloe vera: A preliminary randomized controlled clinical trial. J Altern Complement Med, 23, 858–865.
168.
SalemAH, FletcherCV, and BrundageRC. (2014). Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrob Agents Chemother, 58, 136–143.
169.
SalemML. (2005). Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol, 5, 1749–1770.
170.
SangkitpornS, ShideL, KlinbuayaemV, et al. (2005). Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian J Trop Med Public Health, 36, 704–708.
171.
SarewitzD. (2015). CRISPR: Science can't solve it. Nature, 522, 413–414.
172.
SarrisJ, FavaM, SchweitzerI, and MischoulonD. (2012). St John's Wort (Hypericum perforatum) versus Sertraline and Placebo in major depressive disorder: Continuation data from a 26-week RCT. Pharmacopsychiatry, 45, 275–278.
173.
SchlumbergerM, AbdelmoumeneN, DelisleMJ, and CouetteJE. (1995). Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. Br J Cancer, 71, 363–365.
174.
SeedatYK, and RaynerBL. (2011). South African Hypertension Guideline 2011. S Afr Med J, 102, 57–83.
175.
SegrèD, DelunaA, ChurchGM, and KishonyR. (2005). Modular epistasis in yeast metabolism. Nat Genet, 37, 77–83.
176.
Sharrif MoghaddasiM, and Kumar VermaS. (2011). Aloe vera their chemicals composition and applications: A review. Int J Biol Med, 2, 466–471.
177.
SieberM, BredenfeldH, JostingA, et al. (2003). 14-Day Variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's lymphoma study group. J Clin Oncol, 21, 1734–1739.
178.
SinghV, RaidooDM, and HarriesCS. (2004). BMC Complementary and The prevalence, patterns of usage and people's attitude towards complementary and alternative medicine (CAM) among the Indian community in Chatsworth, South Africa. BMC Complement Altern Med, 4, 3.
179.
SlamonDJ, Leyland-JonesB, ShakS, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783–792.
SoccioRE, ChenER, and LazarMA. (2014). Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab, 20, 573–591.
182.
SpragueBL, Trentham-DietzA, and RemingtonPL. (2011). The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control, 22, 125–134.
183.
StöhrW, BackD, DunnD, et al. (2008). Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir Ther, 13, 675–685.
184.
SwartM, EvansJ, SkeltonM, et al. (2015). An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3′-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. Front Genet, 6, 356.
185.
SwerdlowAJ, JonesME, and British Tamoxifen Second Cancer StudyG. (2005). Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study. J Natl Cancer Inst, 97, 375–384.
186.
TaixiangW, WeiX, YangX, and ZhiyuC. (2007). Medicinal herbs for esophageal cancer. In: Cochrane Database of Systematic Reviews. TaixiangW, ed. Chichester, UK: John Wiley & Sons, Ltd., p. CD004520.
187.
TanakaTN, AllojuSK, OhDK, and CohenEEW. (2015). Thyroid cancer: Molecular pathogenesis, tyrosine kinase inhibitors, and other new therapies. Am J Hematol/Oncol®, 11, 5–9.
188.
TeschkeR, LarreyD, MelchartD, and DananG. (2016). Traditional Chinese medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines, 3, 18.
189.
TewWP, KelsenDP, and IlsonDH. (2005). Targeted therapies for esophageal cancer. Oncologist, 10, 590–601.
190.
ThakarK, NoveroA, DasA, et al. (2014). CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res, 2, 12.
191.
ThomfordN, DzoboK, ChoperaD, et al. (2015). Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals, 8, 637–663.
192.
ThomfordN, DzoboK, ChoperaD, et al. (2016a). In vitro reversible and time-dependent CYP450 inhibition profiles of medicinal herbal plant extracts newbouldia laevis and cassia abbreviata: Implications for herb-drug interactions. Molecules, 21, 891.
193.
ThomfordNE, MkhizeB, DzoboK, et al. (2016b). African lettuce (Launaea taraxacifolia) displays possible anticancer effects and herb-drug interaction potential by CYP1A2, CYP2C9, and CYP2C19 inhibition. OMICS, 20, 528–537.
194.
TörünT, GüngörG, OzmenI, et al. (2005). Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 9, 1373–1377.
195.
TsaiYT, LaiJN, LoPC, ChenCN, and LinJG. (2017). Prescription of Chinese herbal products is associated with a decreased risk of invasive breast cancer. Medicine (Baltimore), 96, e7918.
196.
UrbanMF. (2015). Genomics in medicine: From promise to practice. S Afr Med J, 105, 545.
197.
VacekJ, KlejdusB, and KubánV. (2007). [Hypericin and hyperforin: Bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect]. Ceska Slov Farm, 56, 62–66.
198.
ValderasJM, StarfieldB, SibbaldB, SalisburyC, and RolandM. (2009). Defining comorbidity: Implications for understanding health and health services. Ann Fam Med, 7, 357–363.
199.
VandammeD, MinkeBA, FitzmauriceW, KholodenkoBN, and KolchW. (2014). Systems biology-embedded target validation: Improving efficacy in drug discovery. Wiley Interdiscip Rev Syst Biol Med, 6, 1–11.
200.
Van OlmenJ, SchellevisF, Van DammeW, et al. (2012). Management of chronic diseases in sub-saharan Africa: Cross-fertilisation between HIV/AIDS and diabetes care. J Trop Med, 2012, 349312.
201.
Van WaterschootRA, Ter HeineR, WagenaarE, et al. (2010). Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol, 160, 1224–1233.
202.
VentolaCL. (2013). Role of pharmacogenomic biomarkers in predicting and improving drug response: Part 1: The clinical significance of pharmacogenetic variants. Pharm Ther, 38, 545–560.
203.
WangB, RosanoJM, CheheltaniRE, AcharyMP, and KianiMF. (2010). Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv, 7, 1159–1173.
204.
WangJ, and XiongX. (2012). Control strategy on hypertension in chinese medicine. Evid Based Complement Alternat Med 2012, 284847.
205.
WangJ, and XiongX. (2013). Evidence-based chinese medicine for hypertension. Evid Based Complement Alternat Med 2013, 978398.
206.
WangJ, YangF-Z, ZhaoM, et al. (2006). Randomized double-blinded and controlled clinical trial on treatment of HIV/AIDS by Zhongyan-4. Chin J Integr Med, 12, 6–11.
207.
WangX, ZhangA, ZhouX, et al. (2016). An integrated chinmedomics strategy for discovery of effective constituents from traditional herbal medicine. Sci Rep, 6, 18997.
208.
WardBA, GorskiJC, JonesDR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther, 306, 287–300.
209.
WarmackTS, EstesMA, HeldenbrandS, and FranksAM. (2009). β-adrenergic antagonists in hypertension: A review of the evidence. Ann Pharmacother, 43, 2031–2043.
210.
WeitzmanSP, and CabanillasME. (2015). The treatment landscape in thyroid cancer: A focus on cabozantinib. Cancer Manag Res, 7, 265–278.
211.
WenL, LiuY-F, JiangC, et al. (2018). Comparative proteomic profiling and biomarker identification of traditional Chinese medicine-based HIV/AIDS syndromes. Sci Rep, 8, 4187.
212.
WHO. (2007). Prevention of Cardiovascular Disease. In: Pocket Guidelines for Assessment and Management of Cardiovascular Risk. WHO, ed. Geneva, Switzerland: World Health. Organisation.
213.
WishartDS. (2016). Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov, 15, 473–484.
214.
WolffJL, StarfieldB, and AndersonG. (2002). Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med, 162, 2269–2276.
215.
WuAH, KurianAW, KwanML, et al. (2015). Diabetes and other comorbidities in breast cancer survival by race/ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol Biomarkers Prev, 24, 361–368.
216.
XiaoH, HuangJH, ZhangXW, et al. (2017). Identification of potential diagnostic biomarkers of acute pancreatitis by serum metabolomic profiles. Pancreatology, 17, 543–549.
217.
XiongX, YangX, LiuY, et al. (2013). Chinese herbal formulas for treating hypertension in traditional Chinese medicine: Perspective of modern science. Hypertens Res, 36, 570–579.
218.
YehGY, EisenbergDM, KaptchukTJ, and PhillipsRS. (2003). Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care, 26, 1277–1294.
219.
ZangerUM, and SchwabM. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138, 103–141.
220.
ZhangH-H, and GuoX-L. (2016). Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol, 78, 13–26.
221.
ZhouL, WangK, LiQ, et al. (2016). Clinical proteomics-driven precision medicine for targeted cancer therapy: Current overview and future perspectives. Expert Rev Proteomics, 13, 367–381.
222.
ZollarsE, CourtneySM, WolfBJ, et al. (2016). Clinical application of a modular genomics technique in systemic lupus erythematosus: Progress towards precision medicine. Int J Genomics 2016, 7862962.
